A case for immunosuppression for myoblast transplantation in Duchenne muscular dystrophy

Molecular Therapy

Volumn 17, Issue 7, 2009, Pages 1122-1124

  Tremblay, Jacques P ^a   Skuk, Daniel ^a   Palmieri, Benjamino ^b   Rothstein, David M ^c  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; DYSTROPHIN; GANCICLOVIR; TACROLIMUS;

ALLOTRANSPLANTATION; CELL BASED GENE THERAPY; CLINICAL TRIAL; DUCHENNE MUSCULAR DYSTROPHY; GASTROCNEMIUS MUSCLE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LYMPHOMA; MUSCLE BIOPSY; MUSCLE CELL; MYOBLAST; NONHUMAN; NOTE; PROTEIN EXPRESSION; SATELLITE CELL;

HUMANS; IMMUNOSUPPRESSION; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; TISSUE THERAPY;

EID: 67649838602     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.125     Document Type: Note

References (23)

1. Watt, DJ, Morgan, JE and Partridge, TA (1984). Use of mononuclear precursor cells to insert allogeneic genes into growing mouse muscles. Muscle Nerve 7: 741-750.
2. Partridge, TA, Morgan, JE, Coulton, GR, Hoffman, EP and Kunkel, LM (1989). Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337: 176-179.
3. Gussoni, E, Pavlath, GK, Lanctot, AM, Sharma, KR, Miller, RG, Steinman, L et al. (1992). Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 356: 435-438.
4. Tremblay, JP, Malouin, F, Roy, R, Huard, J, Bouchard, JP, Satoh, A et al. (1993). Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant 2: 99-112.
5. Tremblay, JP, Bouchard, JP, Malouin, F, Théau, D, Cottrell, F, Collin, H et al. (1993). Myoblast transplantation between monozygotic twin girl carriers of Duchenne muscular dystrophy. Neuromuscul Disord 3: 583-592.
6. Mendell, JR, Kissel, JT, Amato, AA, King, W, Signore, L, Prior, TW et al. (1995). Myoblast transfer in the treatment of Duchenne's muscular dystrophy [comments]. N Engl J Med 333: 832-838.
7. Kinoshita, I, Vilquin, JT, Guerette, B, Asselin, I, Roy, R and Tremblay, JP (1994). Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 17: 1407-1415.
8. Kinoshita, I, Roy, R, Dugré, FJ, Gravel, C, Roy, B, Goulet, M et al. (1996). Myoblast transplantation in monkeys: Control of immune response by FK506. J Neuropathol Exp Neurol 55: 687-697.
9. Skuk, D, Roy, B, Goulet, M and Tremblay, JP (1999). Successful myoblast transplantation in primates depends on appropriate cell delivery and induction of regeneration in the host muscle. Exp Neurol 155 22-30.
10. Skuk, D, Goulet, M, Roy, B and Tremblay, JP (2000). Myoblast transplantation in whole muscle of nonhuman primates. J Neuropathol Exp Neurol 59: 197-206.
11. Skuk, D, Goulet, M, Roy, B and Tremblay, JP (2002). Efficacy of myoblast transplantation in non-human primates following simple intramuscular cell injections: Towards defining strategies applicable to humans. J Exp Neurol 175: 112-126.
12. Skuk, D, Goulet, M, Roy, B, Chapdelaine, P, Bouchard, JP, Roy, R et al. (2006). Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol 65: 371-386.
13. Skuk, D, Roy, B, Goulet, M, Chapdelaine, P, Bouchard, JP, Roy, R et al. (2004). Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol Ther 9: 475-482.
14. Skuk, D, Goulet, M, Roy, B, Piette, V, Côté, CH, Chapdelaine, P et al. (2007). First test of a "high-density injection" protocol for myogenic cel transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: Eighteen months follow-up. Neuromuscul Disord 17: 38-46.
15. Opelz, G and Dohler, B (2004). Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 4: 222-230.
16. Webster, AC, Woodroffe, RC, Taylor, RS, Chapman, JR and Craig, JC (2005). Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 331: 810.
17. Dharnidharka, VR, Ho, PL, Stablein, DM, Harmon, WE and Tejani, AH (2002). Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 6: 396-399.
18. Bhimma, R, Adhikari, M, Asharam, K and Connolly, C (2006). Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol 26: 544-551.
19. Bakker, NA and van Imhoff, GW (2007). Post-transplant lymphoproliferative disorders: From treatment to early detection and prevention? Haematologica 92: 1447-1450.
20. Andrei, G, De Clercq, E and Snoeck, R (2009). Drug targets in cytomegalovirus infection. Infect Disord Drug Targets 9: 201-222.
21. Funch, DP, Walker, AM, Schneider, G, Ziyadeh, NJ and Pescovitz, MD (2005). Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5: 2894-2900.
22. Gold, R and Schneider-Gold, C (2008). Current and future standards in treatment of myasthenia gravis. Neurotherapeutics 5: 535-541.
23. Szeto, CC, Kwan, BC, Lai, FM, Tam, LS, Li, EK, Chow, KM et al. (2008). Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 47: 1678-1681.